HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. / Bohlius, Julia; Schmidlin, Kurt; Boué, François; Fätkenheuer, Gerd; May, Margaret; Caro-Murillo, Ana Maria; Mocroft, Amanda; Bonnet, Fabrice; Clifford, Gary; Paparizos, Vassilios; Miro, Jose M; Obel, Niels; Prins, Maria; Chêne, Geneviève; Egger, Matthias; Collaboration of Observational HIV Epidemiological Research Europe.
I: Blood, Bind 117, Nr. 23, 09.06.2011, s. 6100-8.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes
AU - Bohlius, Julia
AU - Schmidlin, Kurt
AU - Boué, François
AU - Fätkenheuer, Gerd
AU - May, Margaret
AU - Caro-Murillo, Ana Maria
AU - Mocroft, Amanda
AU - Bonnet, Fabrice
AU - Clifford, Gary
AU - Paparizos, Vassilios
AU - Miro, Jose M
AU - Obel, Niels
AU - Prins, Maria
AU - Chêne, Geneviève
AU - Egger, Matthias
AU - Collaboration of Observational HIV Epidemiological Research Europe
PY - 2011/6/9
Y1 - 2011/6/9
N2 - The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied the incidence and outcomes of HL, and compared CD4¿ T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1-infected patients (median age, 36 years; 70% male; median CD4 cell count, 234 cells/µL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% confidence interval [CI], 39.3-61.2) per 100,000 person-years, and similar on cART and not on cART (P = .96). The risk of HL declined as the most recent (time-updated) CD4 count increased: the adjusted hazard ratio comparing more than 350 with less than 50 cells/µL was 0.27 (95% CI, 0.08-0.86). Sixty-one HL cases diagnosed on cART were matched to 1652 controls: during the year before diagnosis, cases lost 98 CD4 cells (95% CI, -159 to -36 cells), whereas controls gained 35 cells (95% CI, 24-46 cells; P <.0001). The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.
AB - The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied the incidence and outcomes of HL, and compared CD4¿ T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1-infected patients (median age, 36 years; 70% male; median CD4 cell count, 234 cells/µL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% confidence interval [CI], 39.3-61.2) per 100,000 person-years, and similar on cART and not on cART (P = .96). The risk of HL declined as the most recent (time-updated) CD4 count increased: the adjusted hazard ratio comparing more than 350 with less than 50 cells/µL was 0.27 (95% CI, 0.08-0.86). Sixty-one HL cases diagnosed on cART were matched to 1652 controls: during the year before diagnosis, cases lost 98 CD4 cells (95% CI, -159 to -36 cells), whereas controls gained 35 cells (95% CI, 24-46 cells; P <.0001). The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.
U2 - http://dx.doi.org/10.1182/blood-2010-08-301531
DO - http://dx.doi.org/10.1182/blood-2010-08-301531
M3 - Journal article
VL - 117
SP - 6100
EP - 6108
JO - Blood
JF - Blood
SN - 0006-4971
IS - 23
ER -
ID: 40186098